SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " cdmo " 17 found 🔀 AI-powered Shuffle
Radiopharma player PharmaLogic snaps up Lantheus' CDMO business, plant as Curium acquisition advances
With Lantheus in the process of being bought out by fellow radiopharmaceutical player Curium, the company is offloading its CDMO business and a U.S. | With Lantheus in the process of being bought out by fellow radiopharmaceutical player Curium, the company is offloading its CDMO business and a U.S. manufacturing facility to another nuclear medicine specialist, PharmaLogic.
Merck KGaA to Divest CDMO Business to Lonza
Merck KGaA to Divest CDMO Business to Lonza /
Recon: Merck KGaA to exit CDMO business; Karyopharm to sell itself in bankruptcy
Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.
Lonza bets big on US growth, snaps up Merck KGaA’s CDMO business
In a major reshaping of the pharmaceutical contract manufacturing landscape, Lonza has struck a deal to acquire the CDMO business of Merck KGaA. | Lonza will purchase the German Merck’s U.S.-based CDMO network for mid-triple-digit million euros. Besides five sites, the deal will bolster Lonza’s prowess in rapidly growing sectors such as cell and gene therapy, bioconjugates, viral vectors and advanced drug-delivery technologies.
Merck Sells Its CDMO Business to Lonza
Merck is streamlining its portfolio in the Life Science division and selling its CDMO business to Lonza.
Merck KGaA, Darmstadt, Germany, to Divest CDMO Business to Lonza
Merck KGaA, Darmstadt, Germany, to Divest CDMO Business to Lonza Darmstadt, Germany, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Lonza, a global contract development and manufacturing organization, to acquire the CDMO business of Merck KGaA, Darmstadt, GermanyTransaction sharpens the focus of Life Science business sector of Merck KGaA, Darmstadt, Germany, and provides the CDMO business with a strong platform for its next phase of development Life Science sector’s broad portfolio of consumables, technologi
Merck to Divest CDMO Business to Lonza
Merck to Divest CDMO Business to Lonza Darmstadt, Germany, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Lonza, a global contract development and manufacturing organization, to acquire the CDMO business of Merck Transaction sharpens the focus of Merck’s Life Science business sector and provides the CDMO business with a strong platform for its next phase of development Life Science sector’s broad portfolio of consumables, technologies and services will continue to equip pharmaceutical, biotechnology and CDMO
Dealroom.co | Life Science Connect buys PharmaSource and CDMO Live from Life Science Networks
What's the deal? In June 2026, Life Science Connect, the US-base…
Scinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing Agreement
Committed Customer Orders¹ reach approximately $7.6 million, up approximately 300% from $1.9 million at year-end 2025 Agreement with a U.S. based,...
Committed customer orders at Scinai reach about $7.6 million, up about 300%.
Potential added fees of $5.85 million are indicative and uncommitted; clinical manufacturing under the agreement is planned to start in January 2027.
Minaris Adds Dedicated Viral Vectors Business Unit, Splitting Into Three Specialized Divisions
Minaris, the Philadelphia-based global cell and gene therapy CDMO and multimodal contract testing organization, announced on September 29, 2026 the addition…
Minaris Evolves Business Model with Addition of Dedicated Viral Vectors Business Unit
/PRNewswire/ -- Minaris, a global cell and gene therapy (CGT) CDMO and multimodal contract testing organization, today announced the addition of a dedicated...
4 CDMOs to consider when outsourcing manufacturing
Contract development and manufacturing organizations looking to do business with biopharmas include Lonza, which has more than 30 sites, and Samsung Biologics, which recently announced a planned acquisition of another CDMO.
Pace appoints Andy Fenny as president to drive life science growth
Pace, a science and technology company, has appointed Andrew (Andy) Fenny as president of Pace Life Sciences, the organization’s life sciences division, to lead the business into its next phase of strategic growth with a focus on expanding support and capacity for pharmaceutical and biotech clients across the development cycle.
Country music star teasing retirement after 3 decades: ‘Don’t have another 30 in me’
The singer has been thinking about calling it a career.
BioHarvest Sciences Appoints New Head of Business Development for its CDMO Division
Business development appointment is aligned with securing long-term customers for development and manufacturing partnershipsVancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - May 13, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced the appointment of Nedira Salzman-Frenkel to Vice President of Business Development. Ms....
New York Jets Flight Connections 02/22/26
Happy Sunday, Jets fans! Here are your daily links to kick your day off. Michael Nania – Which Jets free agents are worth keeping at their market values?\ Michael Nania – NY Jets’ Breece Hall pushes for ‘better infrastructure’ with ‘Free20’ Antwan Staley – Jets should avoid drafting QB in 2026 NFL Draft, says NFL […]